Kagocel, tablets 12 mg 30 pcs
€21.90 €20.94
Pharmacotherapeutic group: Antiviral agent.
ATX CODE: [J05AX]
Pharmacological properties
Pharmacodinamics
The main mechanism of action of Kagocel® is the ability to induce production of interferons. Kagocel® causes formation of so-called late interferons in the human body, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes production of interferons in almost all cell populations participating in antiviral response: T- and B- lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When oral administration of one dose of Kagocel® interferon titer in blood serum reaches its maximum values after 48 hours. Interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine when taking Kagocel® orally does not coincide with the dynamics of circulating interferon titers. In serum interferon production reaches high values only 48 hours after Kagocel® administration, while in the intestine maximum interferon production is observed after 4 hours.
Cagocel® when administered in therapeutic doses is non-toxic and does not accumulate in the body. The drug has no mutagenic and teratogenic properties, is not carcinogenic and has no embryotoxic effect.
The drug is most effective when used with Kagocel® not later than the 4th day after the onset of an acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.
Pharmacokinetics
24 hours after administration Kagocel® accumulates in the body mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel® in brain is due to the high molecular weight of the drug, making it difficult to penetrate through the blood-brain barrier. In blood plasma the drug is mainly in bound form.
When daily repeated administration of Kagocel® the volume of distribution varies over a wide range in all organs studied. Accumulation of the drug in the spleen and lymph nodes is particularly pronounced. When administered orally, about 20% of the administered drug dose enters the general bloodstream. Absorbed drug circulates in blood mainly in macromolecule-bound form: with lipids – 47%, with proteins – 37%. The unbound part of the drug is about 16%. </Excretion: the drug is excreted mainly through the intestine: 88% of the administered dose is excreted from the body through 7 days after administration, including 90% through the intestine and 10% – through the kidneys. In the exhaled air the drug was not detected.
Indications
Kagocel® is used in adults and children over the age of 3 years as a preventive and therapeutic agent for influenza and other acute respiratory viral infections (ARVI), as well as a therapeutic agent for herpes in adults.
Pharmacological effect
PHARMACOTHERAPEUTIC GROUP: Antiviral agent.
ATX CODE: [J05AX]
PHARMACOLOGICAL PROPERTIES
PHARMACODYNAMICS
The main mechanism of action of Kagocel® is the ability to induce the production of interferons. Kagocel® causes the formation in the human body of so-called late interferons, which are a mixture of α- and β-interferons with high antiviral activity. Kagocel® causes the production of interferons in almost all cell populations involved in the body’s antiviral response: T- and B-lymphocytes, macrophages, granulocytes, fibroblasts, endothelial cells. When one dose of Kagocel® is taken orally, the interferon titer in the blood serum reaches its maximum values after 48 hours. The body’s interferon response to Kagocel® administration is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine when Kagocel® is taken orally does not coincide with the dynamics of circulating interferon titers. In the blood serum, the production of interferons reaches high values only 48 hours after taking Kagocel®, while in the intestine the maximum production of interferons is observed after 4 hours.
Kagocel®, when prescribed in therapeutic doses, is non-toxic and does not accumulate in the body. The drug does not have mutagenic or teratogenic properties, is not carcinogenic and does not have embryotoxic effects.
The greatest effectiveness in treatment with Kagocel® is achieved when it is prescribed no later than the 4th day from the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the infectious agent.
PHARMACOKINETICS
24 hours after administration to the body, Kagocel® accumulates mainly in the liver, and to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are observed in adipose tissue, heart, muscles, testes, brain, blood plasma. The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which makes it difficult to penetrate the blood-brain barrier. In the blood plasma the drug is found predominantly in bound form.
With daily repeated administration of Kagocel®, the volume of distribution varies widely in all organs studied. The accumulation of the drug is especially pronounced in the spleen and lymph nodes. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids – 47%, with proteins – 37%. The unbound portion of the drug is about 16%.
Excretion: the drug is excreted from the body mainly through the intestines: 7 days after administration, 88% of the administered dose is excreted from the body, including 90% through the intestines and 10% through the kidneys. The drug was not detected in exhaled air.
Special instructions
To achieve a therapeutic effect, Kagocel® should be taken no later than the fourth day from the onset of the disease.
Active ingredient
Kagocel
Composition
Active substance: Kagocel® 12 mg.
Excipients: potato starch – 10 mg, calcium stearate – 0.65 mg, Ludipress (composition: lactose monohydrate, povidone (Kollidon 30), crospovidone (Kollidon CL)) – to obtain a tablet weighing 100 mg.
Pregnancy
Due to the lack of necessary clinical data, Kagocel® is not recommended for use during pregnancy and lactation.
Contraindications
– Pregnancy and lactation;
– Age up to 3 years;
– Hypersensitivity to the components of the drug;
– Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Side Effects
Allergic reactions may develop.
If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.
Interaction
Kagocel® combines well with other antiviral drugs, immunomodulators and antibiotics (additive effect).
Overdose
In case of accidental overdose, it is recommended to prescribe plenty of fluids and induce vomiting.
Storage conditions
In a place protected from light at a temperature not exceeding 25 C.
Keep out of the reach of children.
Shelf life
4 years. After the expiration date indicated on the packaging, the drug should not be used.
Manufacturer
Nearmedic Pharma, Russia
Shelf life | 4 years. After the expiration date indicated on the package, the drug should not be used. |
---|---|
Conditions of storage | In the dark place at a temperature not exceeding 25 C. Keep out of reach of children. |
Manufacturer | Niarmedic Pharma, Russia |
Medication form | pills |
Brand | Niarmedic Pharma |
Other forms…
Related products
Buy Kagocel, tablets 12 mg 30 pcs with delivery to USA, UK, Europe and over 120 other countries.